Analysis of the transmission rate of SARS-CoV-2 Omicron subvariants BA.5.2 and BF.7 based on COVID-19 surveillance data.

Author:

Ke-Wei 1ORCID,Qian-Qian 2

Affiliation:

1. Zhu

2. Liao

Abstract

Abstract Background The Chinese government, announced new 10 measures for COVID-19 response on December 7, 2022, which meant the thorough abolishment of the dynamic zero-COVID-19 policy. The actual number of SARS-CoV-2-infected residents was much larger than the official data due to the cancellation of large-scale nucleic acid testing. Methods This work is a re-analysis of published COVID-19 data. The COVID-19 surveillance data were derived from Human-Society Communication, which is a public service agency for employment. The information of the main endemic strains of SARS-CoV-2 in the Chinese mainland during the Omicron wave obtained from the Chinese Center for Disease Control and Prevention. Human-Society Communication issued online questionnaires of COVID-19 to all Chinese residents via the WeChat Public Account during December 20–21, 2022. Thereafter, Human-Society Communication issued online questionnaires of COVID-19 for the second time on December 26, 2022. Results A total of 122,806 residents participated in the first online questionnaire survey during the two days. The results showed that 74,689 participants (60.8%) were infected with SARS-CoV-2 Omicron variants. For the second online questionnaire survey, a total of 47,897 residents participated in the survey in a day. The results showed that the infection rate of COVID-19 in the Chinese mainland was increased from 60.8–73.5% during December 21–26, 2022. The main endemic strains of SARS-CoV-2 were BA.5.2 and BF.7 according to the analysis results of SARS-CoV-2 genome sequences. Conclusions Both SARS-CoV-2 Omicron subvariants BA.5.2 and BF.7 had extremely strong transmissibility, and large-scale COVID-19 infections posed unprecedented challenges on the Chinese mainland.

Funder

Guangxi Zhuang Autonomous Region Health and Family Planning Commission

Publisher

Research Square Platform LLC

Reference13 articles.

1. 1. National Health Commission of the People's Republic of China. Notification of futher optimization and implementation of prevention and control measures against COVID-19. http://www.nhc.gov.cn/xcs/gzzcwj/202212/8278e7a7aee34e5bb378f0e0fc94e0f0.shtml. 2022 Accessed December 7 2022.

2. 2. National Health Commission of the People's Republic of China. Interpretation and reply of the notification of futher optimization and implementation of prevention and control measures against COVID-19. http://www.nhc.gov.cn/xcs/fkdt/202212/3b3c4f4c101e47ac8c2792c1de079561.shtml. 2022 Accessed December 7 2022.

3. 3. Sun D-X. A total of 3.451677 billion doses of COVID-19 vaccines had been vaccinated by the end of December 13, 2022; 2022.

4. 4. Fan Y, Li X, Zhang L, Wan S, Zhang L, Zhou F. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduct Target Ther. 2022;7:141.

5. 5. Shrestha LB, Foster C, Rawlinson W, Tedla N, Bull RA. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission. Rev Med Virol. 2022;32:e2381.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3